RNA编辑技术市场－全球产业规模、份额、趋势、机会和预测，按RNA类型、应用、技术、地区和竞争格局划分，2020-2030年预测

2024年全球RNA编辑技术市场规模为2.6228亿美元，预计2030年将以7.16%的复合年增长率成长至3.9716亿美元。 RNA编辑技术是指在RNA分子转录后，透过分子过程精确修饰RNA分子内的特定核苷酸序列，这与对基因组DNA的永久性改变截然不同。该技术能够靶向纠正基因突变，并调控基因表达，从而应用于治疗、研究和诊断等领域。市场扩张的主要驱动力是精准医疗需求的不断增长、基于CRISPR的RNA编辑工具的显着进步以及对RNA编辑研究投入的持续增加。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球RNA编辑技术市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依RNA类型（信使RNA修饰、转移RNA修饰、核醣体RNA修饰）
  • 按申请（癌症、遗传性疾病、暂时性疾病）
  • 按技术（插入/删除、脱氨基）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美RNA编辑技术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲RNA编辑技术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区RNA编辑技术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲RNA编辑技术市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美RNA编辑技术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球RNA编辑技术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• ProQR Therapeutics NV
• Sirna Therapeutics, Inc.
• Shape Therapeutics, Inc.
• Korro Bio, Inc.
• Beam Therapeutics, Inc.
• QIAGEN NV
• UniQure NV (UniQure)
• LAVA Therapeutics NV
• argenx SE
• Arrowhead Pharmaceuticals, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global RNA Editing Technologies Market, valued at USD 262.28 Million in 2024, is projected to experience a CAGR of 7.16% to reach USD 397.16 Million by 2030. RNA editing technologies involve molecular processes that precisely modify specific nucleotide sequences within an RNA molecule after its transcription, distinct from permanent alterations to the genomic DNA. This enables targeted corrections of genetic mutations and modulation of gene expression for therapeutic, research, and diagnostic applications. The market's expansion is fundamentally driven by the increasing demand for precision medicine, significant advancements in CRISPR-based RNA editing tools, and growing investments in RNA editing research.

Key Market Drivers

The global RNA editing technologies market is profoundly influenced by two pivotal factors: significant advancements in RNA editing technologies and the increasing demand for precision and personalized medicine. Ongoing innovation in advanced gene editing platforms, particularly CRISPR-based systems and enhanced delivery mechanisms, continues to broaden the therapeutic applicability of RNA editing. For instance, according to the Innovative Genomics Institute, in March 2024, the UK's Medicines and Healthcare Products Regulatory Agency approved Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia in November 2023, with subsequent FDA approval for sickle cell disease in December 2023, marking the first regulatory clearances for a CRISPR-based therapy.

Key Market Challenges

The technical complexity associated with efficient delivery and precise targeting systems for RNA editing components within specific cells and tissues represents a significant impediment to market expansion. This challenge directly affects the progression and success of therapeutic development by prolonging research and development timelines and escalating costs. The difficulty in developing safe and effective methods to introduce RNA editing tools precisely into target cells, without off-target effects or degradation, limits the scalability and broad application of these advanced therapies.

Key Market Trends

Increased cross-sectoral collaborations and partnerships are significantly driving growth in the Global RNA Editing Technologies Market by fostering shared expertise and resources. These alliances between biotechnology firms, pharmaceutical companies, and academic institutions accelerate the complex research and development cycle of RNA editing solutions. For example, in September 2024, Prime Medicine announced a strategic research collaboration and license agreement with Bristol Myers Squibb, which included a $55 million upfront payment and a $55 million equity investment, to develop ex vivo T-cell therapies using Prime Editing technology, demonstrating significant financial commitment to such joint ventures.

Key Market Players

• ProQR Therapeutics NV
• Sirna Therapeutics, Inc.
• Shape Therapeutics, Inc.
• Korro Bio, Inc.
• Beam Therapeutics, Inc.
• QIAGEN N.V.
• UniQure NV (UniQure)
• LAVA Therapeutics N.V.
• argenx SE
• Arrowhead Pharmaceuticals, Inc.

Report Scope:

In this report, the Global RNA Editing Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Editing Technologies Market, By Type of RNA:

• Messenger RNA Modification
• Transfer RNA Modification
• Ribosomal RNA Modification

RNA Editing Technologies Market, By Application:

• Cancer
• Genetic Disorders
• Temporary Maladies

RNA Editing Technologies Market, By Technique:

• Insertion/Deletion
• Deamination

RNA Editing Technologies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global RNA Editing Technologies Market.

Available Customizations:

Global RNA Editing Technologies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Editing Technologies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of RNA (Messenger RNA Modification, Transfer RNA Modification, Ribosomal RNA Modification)
  • 5.2.2. By Application (Cancer, Genetic Disorders, Temporary Maladies)
  • 5.2.3. By Technique (Insertion/Deletion, Deamination)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America RNA Editing Technologies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of RNA
  • 6.2.2. By Application
  • 6.2.3. By Technique
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Editing Technologies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of RNA
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technique
  • 6.3.2. Canada RNA Editing Technologies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of RNA
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technique
  • 6.3.3. Mexico RNA Editing Technologies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of RNA
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technique

7. Europe RNA Editing Technologies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of RNA
  • 7.2.2. By Application
  • 7.2.3. By Technique
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Editing Technologies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of RNA
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technique
  • 7.3.2. France RNA Editing Technologies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of RNA
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technique
  • 7.3.3. United Kingdom RNA Editing Technologies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of RNA
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technique
  • 7.3.4. Italy RNA Editing Technologies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of RNA
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technique
  • 7.3.5. Spain RNA Editing Technologies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of RNA
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technique

8. Asia Pacific RNA Editing Technologies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of RNA
  • 8.2.2. By Application
  • 8.2.3. By Technique
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNA Editing Technologies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of RNA
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technique
  • 8.3.2. India RNA Editing Technologies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of RNA
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technique
  • 8.3.3. Japan RNA Editing Technologies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of RNA
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technique
  • 8.3.4. South Korea RNA Editing Technologies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of RNA
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technique
  • 8.3.5. Australia RNA Editing Technologies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of RNA
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technique

9. Middle East & Africa RNA Editing Technologies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of RNA
  • 9.2.2. By Application
  • 9.2.3. By Technique
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNA Editing Technologies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of RNA
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technique
  • 9.3.2. UAE RNA Editing Technologies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of RNA
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technique
  • 9.3.3. South Africa RNA Editing Technologies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of RNA
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technique

10. South America RNA Editing Technologies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of RNA
  • 10.2.2. By Application
  • 10.2.3. By Technique
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNA Editing Technologies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of RNA
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technique
  • 10.3.2. Colombia RNA Editing Technologies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of RNA
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technique
  • 10.3.3. Argentina RNA Editing Technologies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of RNA
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technique

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNA Editing Technologies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ProQR Therapeutics NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sirna Therapeutics, Inc.
• 15.3. Shape Therapeutics, Inc.
• 15.4. Korro Bio, Inc.
• 15.5. Beam Therapeutics, Inc.
• 15.6. QIAGEN N.V.
• 15.7. UniQure NV (UniQure)
• 15.8. LAVA Therapeutics N.V.
• 15.9. argenx SE
• 15.10. Arrowhead Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer